NCT06912087 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06912087
Title	Phase I Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	University of Chicago
Indications	hypopharynx cancer laryngeal squamous cell carcinoma oropharynx cancer nasopharynx carcinoma head and neck squamous cell carcinoma oral squamous cell carcinoma nasal cavity carcinoma
Therapies	Cetuximab + Pembrolizumab + XL092
Age Groups:	adult \| senior
Covered Countries	USA

NCT06912087
Clinical Trial Detail